The Lymphoma Information Network and Healthology Partner to Bring You Multimedia Health Information

Choose your topic:

ADD/ADHD Allergy
Alternative Medicine Alzheimer's Disease
Arthritis Asthma
Beyond Dieting Body Aches and Pains
Breast Cancer Cancer Awareness
Cardio Health Caregiver
Children's Health Colon Cancer
Contraception COPD/Emphysema
Dental Health Diabetes
Epilepsy Erectile Dysfunction
Eye Care Fertility
Fitness Gastrointestinal Health
Glands and Hormones Gynecologic Health
Hair Loss Headache
Healthcare Today Healthy Aging
Heartburn HIV and AIDS
Infectious Diseases Kidney Health
Leukemia Liver Health
Lung Cancer Lymphoma
Multiple Sclerosis Men's Health
Mental Health Nutrition
Multiple Sclerosis Osteoporosis
Parkinson's Disease Pregnancy & Childbirth
Prostate Health Psoriasis
Sexual Health Skin Health
Sleep Disorders Special Events
Stroke Surgeries and Procedures
Teen Health Thyroid Health
Urologic Health Vascular Disease
Women's Health Workplace Health

 

Sponsored Links

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap